2015至2023年美国中毒中心报告的伊伐布雷定暴露
该研究查询美国国家中毒数据系统,收集2015年4月15日至2023年12月31日报告的伊伐布雷定暴露共240例,55.0%在非医疗机构现场处理。139例随访至明确结局,其中60%无效应、14%轻微效应、27%中度效应;最常见症状为心动过缓(36例,15.1%)。儿童暴露占18.8%且均无需干预,故意自伤暴露占17.1%且结局更差,5例成人接受强化治疗(气管插管、血管升压药、心脏起搏、血液透析),无死亡报告。作者认为无症状的成人意外暴露可考虑家庭监测,医学处理难治的暴露可考虑心脏起搏或其他支持措施作为临时手段。
要点
- 240例伊伐布雷定暴露中55.0%在非医疗机构现场处理、未转至医疗机构,最常见症状为心动过缓(36例,15.1%)。
- 139例随访至明确结局者中60%无效应、14%轻微效应、27%中度效应,无死亡报告。
- 儿童暴露占18.8%,无一例需要干预。
- 故意自伤暴露占17.1%,结局更差;5例成人接受气管插管、血管升压药、心脏起搏或血液透析等强化治疗。
- 作者认为无症状的成人意外暴露可考虑家庭监测;医学处理难治的暴露可考虑心脏起搏或其他支持措施作为临时手段。
适用人群与场景
- 2015年4月15日至2023年12月31日向美国中毒中心报告的伊伐布雷定暴露者,年龄分层为儿童(0-5岁)、青少年(6-17岁)、成人(18-64岁)和老年(65岁以上)。
处置流程与药物剂量
- 作者认为,无症状的成人意外伊伐布雷定暴露可考虑家庭监测。
- 作者认为,对医学处理难治的伊伐布雷定暴露,临床医生可考虑心脏起搏或其他支持措施作为临时手段。
- 5例成人接受了强化治疗,包括气管插管、血管升压药、心脏起搏和血液透析。
红旗征与不能漏的情况
- 心动过缓是最常报告的症状,共36例(15.1%)。
- 故意自伤暴露占全部病例的17.1%,且更可能出现更差的结局。
研究设计与关键结果
- 研究类型为对美国国家中毒数据系统®的查询,纳入2015年4月15日至2023年12月31日报告的伊伐布雷定暴露240例,55.0%在非医疗机构现场处理、未转至医疗机构。
- 最常见报告症状为心动过缓,36例(15.1%)。
- 139例随访至明确结局,其中60%无效应、14%轻微效应、27%中度效应。
- 儿童暴露占18.8%,无一例需要干预。
- 故意自伤暴露占17.1%,更可能出现更差结局。
- 5例成人接受强化治疗(气管插管、血管升压药、心脏起搏、血液透析),无伊伐布雷定暴露相关死亡报告。
证据类型、等级与局限
- 证据类型:基于美国国家中毒数据系统®的回顾性中毒中心报告分析。
- 局限:数据来源为回顾性且不完整,仅能研究报告至中毒中心的信息,暴露未经实验室检测确认;未进一步随访的病例可能有其他未报告的治疗和临床效应;向中毒中心报告可能低估伊伐布雷定暴露的真实数量。
对床旁实践的改变
- 作者认为,无症状的成人意外伊伐布雷定暴露可考虑家庭监测。
- 作者认为,对医学处理难治的伊伐布雷定暴露,临床医生可考虑心脏起搏或其他支持措施作为临时手段。
- 儿童暴露占18.8%且均无需干预,故意自伤暴露占17.1%且结局更差。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Ivabradine was approved for use in the United States in 2015 for the management of heart failure. It acts through inhibition of sodium channels found in cardiac myocytes (the "funny" pacemaker current, If), which reduces heart rate without significantly affecting inotropy.
METHODS: We queried the National Poison Data System® for reported ivabradine exposures from April 15, 2015-December 31, 2023. Age was stratified into child (0-5 years), adolescent (6-17 years), adult (18-64 years) and geriatric (65+ years). Other descriptive statistics gathered included patient sex, management site, and medical outcome as coded by America's Poison Centers®.
RESULTS: There were 240 ivabradine exposures, with 55.0% managed on-site and not transferred to a healthcare facility. The most common reported symptom was bradycardia, reported in 36 patients (15.1%). There were 139 cases that were followed to a known outcome. Within this cohort, 60%, 14%, and 27% of patients suffered no effect, minor effect, or moderate effect, respectively. Exposures in children comprised 18.8% of cases; none required intervention. Intentional self-harm exposures comprised 17.1% of all cases and were more likely to have worse outcomes. Five adult patients received intensive therapy (endotracheal intubation, vasopressors, cardiac pacing, hemodialysis). There were no reported deaths from ivabradine exposure.
DISCUSSION: This study has limitations. First, our data source was limited by being retrospective and incomplete; we could only study the information that was reported to poison centers, and exposures were not confirmed by laboratory testing. It is possible that cases without further follow-up had other treatments and clinical effects not reported here. Finally, reports to poison centers likely underestimate the true number of ivabradine exposures.
CONCLUSION: Adults with unintentional, asymptomatic exposures to ivabradine may be candidates for home monitoring. In ivabradine exposures refractory to medical management, clinicians should consider cardiac pacing or other supportive measures as a temporizing measure.
参考来源
- Szczesniak L, Thornton S, Feldman R, et al. Ivabradine exposures reported to United States poison centers 2015-2023. Clin Toxicol (Phila). 2025. PMID: 39991866. doi:10.1080/15563650.2025.2460660
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。